Searched for
DRUG AVASTIN
Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilarAurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...- Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drugBiocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's...
- Biocon tanks 4% as USFDA defers decision on Avastin biosimilar applicationBiocon's arm Biocon Biologics and Mylan, a subsidiary of Viatris Inc, have been informed by the USFDA of a deferred action on the BLA for M...
- USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard revie...
- US FDA accepts Biocon's cancer drug application for reviewBiocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...
- Dr Reddy's launches Roche's Avastin biosimilar in IndiaThe launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio.
- Intas launches biosimilar Bevacizumab with aggressive pricingBiosimilar drugs are the follow on versions of biologic drugs which are composed of sugars, proteins, nucleic acids or complex combinations...
- Government set to release revised biosimilar guidelines in July 2016The ministry expects the final guidelines to uphold the safety and efficacy of biosimilar drugs hitting the Indian market through stringent...
- Reliance Lifesciences launches world's first biosimilar used to treat advanced cancersIn 2014, Reliance had entered into a similar arrangement with Torrent Pharma to sell copies of three drugs -- rituximab, adalimumab and cet...
- Delhi High Court asks Roche to explain lawsuit over Avastin copyRoche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to b...
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.
- Roche moves court to block copies of cancer drug Avastin, A La HerceptinRoche has challenged the regulator and pleaded to block the approvals of the drugs under review, ET learned from highly placed legal source...
- Indian drug regulator backs off over use of Roche’s AvastinThe Drug Controller General of India has passed an order removing an alert notice for the use of Roche’s Avastin (bevacizumab) injection to...
- Roche begins probe into Avastin use for eye ailmentsRoche has initiated an internal investigation following reports the it had been used in certain eye ailments and damaged the vision of 15 p...
- Strides invests in US-based biosimilar companyStrides Arcolab has invested in Oncobiologics Inc, a privately held US-based drug company focussed on biosimilar and novel biologic drug re...
- Cipla to partner Chinese co in selling Roche, Amgen drug clonesCipla, the Indian drugmaker that built a $1-billion business making generic HIV treatments, aims to sell copies of Roche Holding's and Amge...
- Swiss drugmaker Roche completes Genentech takeoverSwiss pharmaceutical giant Roche said it has completed its $46.8 billion takeover of California-based biotech firm Genentech.
- Genentech tells shareholders to reject Roche bidGenentech Inc. says its shareholders should reject a hostile buyout bid from Swiss drugmaker Roche.
- Roche makes 'cheaper' bid for GenentechRoche Holding AG lowered the acquisition price by 2.8% and took the offer for the US cancer-drug developer directly to shareholders.
- Roche files for Avastin to treat breast cancer in EuropeSwiss drugmaker Roche has filed its Avastin drug for use in previously untreated advanced breast cancer in Europe, the company said on Mond...
Load More
